New England Journal of Medicine· 2017Q1· Clinical trial
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- 3,410citations
- Q1SCImago
- 2017year
Short summary
Pembrolizumab significantly extended overall survival by approximately 3 months compared to chemotherapy in patients with advanced urothelial carcinoma progressing after platinum-based treatment.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Surgery
SurgeryMedicine